BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 18604652)

  • 21. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
    Gerardy J
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia.
    Löscher W; Witte U; Fredow G; Ganter M; Bickhardt K
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Jun; 341(6):483-93. PubMed ID: 2118235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
    McKenna DJ; Towers GH; Abbott F
    J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
    Riga MS; Soria G; Tudela R; Artigas F; Celada P
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5-hydroxytryptamine uptake blocker.
    Ashkenazi R; Finberg JP; Youdim MB
    Br J Pharmacol; 1983 Jul; 79(3):765-70. PubMed ID: 6418248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
    Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
    Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
    Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
    Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gestational exposure to nicotine and monoamine oxidase inhibitors influences cocaine-induced locomotion in adolescent rats.
    Franke RM; Belluzzi JD; Leslie FM
    Psychopharmacology (Berl); 2007 Nov; 195(1):117-24. PubMed ID: 17653695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area.
    Chenu F; El Mansari M; Blier P
    Int J Neuropsychopharmacol; 2009 May; 12(4):475-85. PubMed ID: 18700056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abuse liability profile of three substituted tryptamines.
    Gatch MB; Forster MJ; Janowsky A; Eshleman AJ
    J Pharmacol Exp Ther; 2011 Jul; 338(1):280-9. PubMed ID: 21474568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subthalamic 5-HT(1A) and 5-HT(1B) receptor modulation of RU 24969-induced behavioral profile in rats.
    Martinez-Price DL; Geyer MA
    Pharmacol Biochem Behav; 2002 Apr; 71(4):569-80. PubMed ID: 11888548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.
    van den Buuse M; Ruimschotel E; Martin S; Risbrough VB; Halberstadt AL
    Neuropharmacology; 2011; 61(1-2):209-16. PubMed ID: 21501627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
    Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
    J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
    Sagi Y; Driguès N; Youdim MB
    Br J Pharmacol; 2005 Oct; 146(4):553-60. PubMed ID: 16086033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered behavior and alcohol tolerance in transgenic mice lacking MAO A: a comparison with effects of MAO A inhibitor clorgyline.
    Popova NK; Vishnivetskaya GB; Ivanova EA; Skrinskaya JA; Seif I
    Pharmacol Biochem Behav; 2000 Dec; 67(4):719-27. PubMed ID: 11166062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids
    Brito-da-Costa AM; Dias-da-Silva D; Gomes NGM; Dinis-Oliveira RJ; Madureira-Carvalho Á
    Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A switch mechanism between locomotion and mouthing implicated in sensitization to quinpirole in rats.
    Culver KE; Rosenfeld JM; Szechtman H
    Psychopharmacology (Berl); 2000 Aug; 151(2-3):202-10. PubMed ID: 10972466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice.
    Halberstadt AL; Lehmann-Masten VD; Geyer MA; Powell SB
    Psychopharmacology (Berl); 2011 May; 215(1):81-92. PubMed ID: 21153406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term erythrosine B-induced inhibition of the brain regional serotonergic activity suppresses motor activity (exploratory behavior) of young adult mammals.
    Dalal A; Poddar MK
    Pharmacol Biochem Behav; 2009 Jun; 92(4):574-82. PubMed ID: 19264092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.